STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
STAAR Surgical Company, a Delaware corporation, filed its quarterly report (Form 10-Q) for the period ended October 2, 1998. The company manufactures and markets ophthalmic products, including the Implantable Contact Lens and AquaFlo glaucoma drainage device. The reporting period covers the three and nine months ended October 2, 1998, compared to the same periods in 1997.
Key Financial Metrics
| Metric | Nine Months Ended Oct 2, 1998 | Nine Months Ended Oct 3, 1997 |
|---|---|---|
| Total Revenues | $40,985,219 | $33,963,477 |
| Gross Profit | $28,295,350 (69.0% margin) | $26,048,928 (76.7% margin) |
| Operating Income | $6,835,703 | $8,959,654 |
| Net Income | $1,915,573 | $5,766,614 |
| Cash and Cash Equivalents (End of Period) | $3,239,734 | $3,669,387 |
| Total Debt (Current + Long-term) | $10,752,672 | $6,358,452 |
| Current Ratio | 3.2:1 | 3.4:1 (Jan 2, 1998) |
Liquidity: Net working capital increased to $26.6 million from $24.9 million at the beginning of the year. Net cash provided by operating activities was $1.6 million, while net cash used in investing activities was $7.5 million, primarily due to the acquisition of a foreign distributor.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 20.7% year-over-year, driven by a $13.3 million increase in international sales from new foreign subsidiaries and new product rollouts.
- Margin Compression: Gross profit margin declined from 76.7% to 69.0%. This was attributed to higher costs of sales for non-manufactured products from new foreign subsidiaries.
- Expense Increases: Marketing and selling expenses rose to 33.0% of revenue (from 27.7%) due to costs associated with new foreign distributors. General and administrative expenses decreased as a percentage of revenue (12.5% vs 13.7%) due to revenue absorption.
- Accounting Change: The company adopted SOP 98-5, resulting in a one-time write-off of $1.68 million in start-up costs, reported as a cumulative effect of a change in accounting method. This reduced net income significantly for the quarter and nine-month period.
- Acquisition: On January 5, 1998, the company acquired a 60% interest in a foreign distributor for approximately $4.6 million, recording $4.1 million in goodwill.
Outlook, Risks, and Management Commentary
Management Commentary: Management expects cost of sales as a percentage of revenue to decline as the product mix of new subsidiaries shifts toward company-manufactured goods. The company recorded lower royalty revenue ($562,000 less) compared to the prior year.
Year 2000 Compliance: The company has established a steering committee and is following a five-step process (Awareness, Assessment, Renovation, Validation, Implementation). Validation is expected by April 1999, with implementation by June 1999. Costs to date are immaterial, though risks remain regarding external vendors and utilities.
Risks: International operations expose the company to fluctuating exchange rates, foreign government regulations, and political instability. The company also faces competitive pressures on average selling prices for intraocular lenses (IOLs).
Investor Verification Checklist
- Verify the sustainability of the 20.7% revenue growth given the one-time impact of the foreign distributor acquisition.
- Monitor the trend in gross margins as the new subsidiaries transition to manufacturing more products in-house.
- Assess the impact of the $1.68 million start-up cost write-off on future earnings projections.
- Review the progress of Year 2000 compliance, specifically regarding critical external vendors and suppliers.
- Confirm the status of the $2.9 million in notes payable issued to officers and directors for stock option exercises.